Document Detail

Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.
MedLine Citation:
PMID:  22079678     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To identify clinical and pathologic predictors of response to progestin treatment in premenopausal women with complex atypical hyperplasia (CAH) and Grade 1 endometrial adenocarcinoma (Grade 1 EA). METHODS: Forty premenopausal patients with Grade 1 EA or CAH who underwent progestin therapy for a minimum of 8 weeks were retrospectively identified. Patient characteristics and histopathologic features of pretreatment and first follow-up endometrial specimens were evaluated as predictors of resolution, defined as absence of hyperplasia or carcinoma. RESULTS: Kaplan-Meier analysis indicated 63% resolution at 18 months of follow-up. Multivariate classification analysis showed that resolution rates were higher in individuals with a low pre-treatment qualitative abnormal architecture score and a BMI <35 (Standardized Resolution Ratio (SRR)=1.48, p=0.03). The diagnosis of benign endometrium or simple hyperplasia on the first follow-up specimen was highly predictive of resolution (SRR=2.25, p=0.002). Resolution rates were lower among subjects with a high pre-treatment qualitative abnormal architecture score (SRR=0.37, p<0.03) and lowest in subjects whose first follow-up specimen showed persistent complexity, atypia, or carcinoma with adjacent stromal decidualization (SRR=0.24, p=0.002). CONCLUSIONS: Clinical and pathologic parameters can predict response to progestin therapy in premenopausal women with CAH and Grade 1 EA. A low likelihood of resolution is predicted by an unfavorable pre-treatment architectural score and lack of pathological response in the first specimen, despite adjacent stromal decidualization.
Kristine R Penner; Oliver Dorigo; Chisa Aoyama; Nora Ostrzega; Bonnie L Balzer; Jianyu Rao; Christine S Walsh; Ilana Cass; Christine H Holschneider
Related Documents :
21397488 - Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph n...
22090048 - Risk factors for disconcordance between pre and post radical cystectomy stages.
19223898 - Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre...
18370488 - Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure...
2496368 - Impact of initial therapy on survival in recurrent breast cancer.
22085338 - Risk profile of bevacizumab in patients with non-small cell lung cancer: a meta-analysi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-9
Journal Detail:
Title:  Gynecologic oncology     Volume:  -     ISSN:  1095-6859     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier Inc.
Department of Obstetrics and Gynecology, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hematological malignancy associated with polymyositis and dermatomyositis.
Next Document:  Autoimmune disease and gender: Plausible mechanisms for the female predominance of autoimmunity.